Cardinal Capital Management increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 11.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 38,919 shares of the company’s stock after buying an additional 3,876 shares during the quarter. Cardinal Capital Management’s holdings in Novo Nordisk A/S were worth $1,873,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Fisher Asset Management LLC increased its holdings in Novo Nordisk A/S by 3.7% in the 3rd quarter. Fisher Asset Management LLC now owns 12,124,724 shares of the company’s stock worth $583,806,000 after purchasing an additional 433,727 shares in the last quarter. Folketrygdfondet increased its holdings in Novo Nordisk A/S by 13.2% in the 2nd quarter. Folketrygdfondet now owns 6,914,192 shares of the company’s stock worth $296,550,000 after purchasing an additional 803,608 shares in the last quarter. State Street Corp increased its holdings in Novo Nordisk A/S by 64,406.4% in the 1st quarter. State Street Corp now owns 5,593,351 shares of the company’s stock worth $191,740,000 after purchasing an additional 5,584,680 shares in the last quarter. Everett Harris & Co. CA increased its stake in shares of Novo Nordisk A/S by 0.3% in the second quarter. Everett Harris & Co. CA now owns 3,120,155 shares of the company’s stock valued at $133,823,000 after buying an additional 10,610 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Novo Nordisk A/S by 0.5% in the second quarter. Northern Trust Corp now owns 1,975,217 shares of the company’s stock valued at $84,717,000 after buying an additional 9,319 shares during the period. Institutional investors and hedge funds own 6.04% of the company’s stock.
Novo Nordisk A/S (NYSE:NVO) traded up $0.78 during midday trading on Friday, reaching $49.91. The company had a trading volume of 1,238,200 shares, compared to its average volume of 2,164,315. The firm has a market capitalization of $125,281.50, a PE ratio of 21.45, a P/E/G ratio of 2.93 and a beta of 0.63. Novo Nordisk A/S has a fifty-two week low of $30.89 and a fifty-two week high of $50.95.
COPYRIGHT VIOLATION NOTICE: “Cardinal Capital Management Buys 3,876 Shares of Novo Nordisk A/S (NVO)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2017/11/12/novo-nordisk-as-nvo-shares-bought-by-cardinal-capital-management.html.
Several brokerages have recently weighed in on NVO. BidaskClub raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. BNP Paribas cut Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Zacks Investment Research cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Finally, Bank of America Corporation raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, September 6th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $55.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.